Cargando…
Defining the Ideal Patient with Hepatocellular Carcinoma for Second-Line Treatment
BACKGROUND: Second line of treatment of hepatocellular carcinoma (HCC) has notably changed in recent years as three novel drugs with a different mechanism of action have demonstrated to improve survival compared to placebo; thus, there is a need to better define the profile of optimal candidates to...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Hindawi
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7321521/ https://www.ncbi.nlm.nih.gov/pubmed/32655640 http://dx.doi.org/10.1155/2020/8024124 |